IL318372A - Methods of cancer treatment using anti-tigit antibodies - Google Patents
Methods of cancer treatment using anti-tigit antibodiesInfo
- Publication number
- IL318372A IL318372A IL318372A IL31837225A IL318372A IL 318372 A IL318372 A IL 318372A IL 318372 A IL318372 A IL 318372A IL 31837225 A IL31837225 A IL 31837225A IL 318372 A IL318372 A IL 318372A
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- seq
- antibody
- tigit
- tigit antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (28)
1. CLAIM S 1. A method of cancer treatment, the method comprising administering to a subject an effective amount of anti-TIGIT antibody or antigen-binding fragment thereof that is pH dependent.
2. The method of claim 1, wherein the anti-TIGIT antibody binds to the TIGIT protein at amino acid histidine 76.
3. The method of claim 2, wherein the anti-TIGIT antibody binds to the TIGIT protein at histidine 76 and leucine 73.
4. The method of claim 3, wherein the method comprises administering to a subject an effective amount of a pH dependent antibody or antigen-binding fragment thereof, which specifically binds to human TIGIT and comprises: a heavy chain variable region that comprises a HCDR (Heavy Chain Complementarity Determining Region) 1 of SEQ ID NO: 1, a HCDR2 of SEQ ID NO: 2, and a HCDR3 of SEQ ID NO:3; and a light chain variable region that comprises a LCDR (Light Chain Complementarity Determining Region) 1 of SEQ ID NO:4, a LCDR2 of SEQ ID NO:5, and a LCDR3 of SEQ ID NO:6.
5. The method of claim 4, wherein the anti-TIGIT antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (VH) that comprises SEQ ID NO:7, and a light chain variable region (VL) that comprises SEQ ID NO: 8.
6. The method of claim 1, wherein the anti-TIGIT antibody has enhanced antibody dependent cell mediated cytotoxicity (ADCC) activity.
7. The method of claim 6, wherein the anti-TIGIT antibody has reduced fucosylation.
8. The method of claim 6, wherein the anti-TIGIT antibody has Fc amino acid changes at S239D, and I332E (EU numbering).
9. The method of claim 6, wherein the anti-TIGIT antibody has Fc amino acid changes at S239D, I332E and A330L (EU numbering).
10. The method of any one of claims 7-9, wherein the anti-TIGIT antibody has increased binding affinity to FcγRIIIA-V158 and FcγRIIIA-F158.
11. The method of any one of claims 7-9, wherein the anti-TIGIT antibody has enhanced ADCC in T-regulatory (Treg) cells.
12. The method of any one of claims 7-9, wherein the anti-TIGIT antibody activates Natural Killer (NK) cells.
13. The method of any one of claims 7-9, wherein the anti-TIGIT antibody has increased trogocytosis.
14. The method of claim 1, wherein the method further comprises administering an anti-PD1 antibody which specifically binds human PD1 and comprises: a heavy chain variable region that comprises a HCDR1 of SEQ ID NO: 15, HCDR2 of SEQ ID NO: 16, and HCDR3 of SEQ ID NO: 17; and a light chain variable region that comprises LCDR1 of SEQ ID NO: 18, LCDR2 of SEQ ID NO: 19, and LCDR3 of SEQ ID NO: 20.
15. The method of claim 14, wherein the anti-PD1 antibody or antigen binding fragment thereof which specifically binds human PD1 and comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO:21 and a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 22.
16. The method of claim 14 or 15 wherein the anti-PD1 antibody comprises an IgGconstant domain comprising SEQ ID NO: 23.
17. The method of claim 1, wherein the cancer is selected from the group consisting of breast cancer, colon cancer, pancreatic cancer, head and neck cancer, gastric cancer, kidney cancer, liver cancer, small cell lung cancer, non-small cell lung cancer, esophageal cancer, ovarian cancer, uterine cancer, cervical cancer, skin cancer, mesothelioma, lymphoma, leukemia, myeloma or sarcoma.
18. The method of claim 17, wherein the cancer is non-small cell lung cancer.
19. The method of claim 17, wherein the head and neck cancer is nasopharyngeal cancer.
20. The method of claim 17, wherein the esophageal cancer is esophageal squamous cell carcinoma (ESCC).
21. The method of claim 17, wherein the cancer is uterine cancer.
22. The method of claim 17, wherein the gastric cancer is gastric or gastroesophageal junction cancer.
23. The method of claim 17, wherein the cervical cancer is recurring or metastatic cervical cancer.
24. The method of claim 17, wherein the cancer is kidney cancer.
25. The method of claim 14, further comprising the administration of chemotherapy.
26. The method of claim 20, wherein the chemotherapy is chemoradiotherapy.
27. The method of claim 1, wherein the anti-PD1 antibody is dosed at 200mg every three weeks.
28. An anti-TIGIT antibody or antigen-binding fragment thereof that is pH dependent for use in a method for cancer treatment.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022105904 | 2022-07-15 | ||
| CN2023084985 | 2023-03-30 | ||
| PCT/CN2023/107563 WO2024012584A1 (en) | 2022-07-15 | 2023-07-14 | Methods of cancer treatment using anti-tigit antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318372A true IL318372A (en) | 2025-03-01 |
Family
ID=89535674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318372A IL318372A (en) | 2022-07-15 | 2023-07-14 | Methods of cancer treatment using anti-tigit antibodies |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4554620A1 (en) |
| JP (1) | JP2025524657A (en) |
| KR (1) | KR20250039403A (en) |
| CN (1) | CN119698295A (en) |
| AU (1) | AU2023305697A1 (en) |
| CA (1) | CA3261847A1 (en) |
| IL (1) | IL318372A (en) |
| MX (1) | MX2025000567A (en) |
| WO (1) | WO2024012584A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202300039T1 (en) * | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| TWI877769B (en) * | 2017-12-30 | 2025-03-21 | 英屬開曼群島商百濟神州有限公司 | Anti-tigit antibodies and their use as therapeutics and diagnostics |
| JP6800191B2 (en) * | 2018-09-21 | 2020-12-16 | ベイジーン スウィッツァーランド ゲーエムベーハー | Anti-PD-1 antibody and its use for treatment and diagnosis |
| KR20220103709A (en) * | 2019-11-21 | 2022-07-22 | 베이진 엘티디 | Methods of treating cancer using an anti-OX40 antibody in combination with an anti-TIGIT antibody |
-
2023
- 2023-07-14 EP EP23839071.0A patent/EP4554620A1/en not_active Withdrawn
- 2023-07-14 KR KR1020257004611A patent/KR20250039403A/en active Pending
- 2023-07-14 IL IL318372A patent/IL318372A/en unknown
- 2023-07-14 AU AU2023305697A patent/AU2023305697A1/en active Pending
- 2023-07-14 CA CA3261847A patent/CA3261847A1/en active Pending
- 2023-07-14 CN CN202380053107.XA patent/CN119698295A/en active Pending
- 2023-07-14 WO PCT/CN2023/107563 patent/WO2024012584A1/en not_active Ceased
- 2023-07-14 JP JP2025501642A patent/JP2025524657A/en active Pending
-
2025
- 2025-01-14 MX MX2025000567A patent/MX2025000567A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119698295A (en) | 2025-03-25 |
| JP2025524657A (en) | 2025-07-30 |
| CA3261847A1 (en) | 2024-01-18 |
| MX2025000567A (en) | 2025-02-10 |
| KR20250039403A (en) | 2025-03-20 |
| EP4554620A1 (en) | 2025-05-21 |
| AU2023305697A1 (en) | 2025-02-20 |
| WO2024012584A1 (en) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276830B1 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JP2024037894A5 (en) | ||
| IL310938A (en) | Anti-ccr8 antibodies and uses thereof | |
| JP2021521843A5 (en) | ||
| JP2024531409A5 (en) | ||
| JP2022533538A5 (en) | ||
| CN112513094A (en) | Antibodies that bind to human HER2, methods of making and uses thereof | |
| JP2023525695A5 (en) | ||
| NZ609619A (en) | Novel egfr-binding molecules and immunoconjugates thereof | |
| JP2021528047A5 (en) | ||
| JP2025038088A5 (en) | ||
| JP2021512652A5 (en) | ||
| JP2024540148A5 (en) | ||
| CN111712521A (en) | CD38 protein antibody and its application | |
| JP2023503396A5 (en) | ||
| JP2024504331A5 (en) | ||
| JP2023502323A5 (en) | ||
| JP2023532248A5 (en) | ||
| CN111246881A (en) | Use of PD-1 antibodies for treating tumors | |
| JP2024519078A5 (en) | ||
| JP2024522075A5 (en) | ||
| RU2025101095A (en) | CANCER TREATMENT METHODS USING ANTIBODIES AGAINST TIGIT | |
| JP2022534624A5 (en) | ||
| JP2023503399A5 (en) | ||
| JP2024517741A5 (en) |